NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC

NANOVIRICIDES, INC.

NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.
NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.
Encapsulation protects remdesivir from metabolism, improving efficacy per company.
Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.
Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.